The role of lipoprotein(a) in the pathogenesis of atherosclerotic cardiovascular disease and its utility as predictor of coronary heart disease events

Current Cardiology Reports

Volumn 3, Issue 5, 2001, Pages 385-390

  Scanu, Angelo M ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN;

ARTERY; BLOOD; CORONARY ARTERY ATHEROSCLEROSIS; HUMAN; METABOLISM; REVIEW; VASCULAR ENDOTHELIUM;

ARTERIES; CORONARY ARTERIOSCLEROSIS; ENDOTHELIUM, VASCULAR; HUMANS; LIPOPROTEIN(A); LIPOPROTEINS, LDL;

EID: 0035458864     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-001-0055-4     Document Type: Article

References (33)

1. Scanu AM, Lawn RM, Berg K: Lipoprotein(a) and Atherosclerosis. Ann Int Med 1991, 115:209-218.
2. Scanu AM, Fless GM: Lipoprotein (a): heterogeneity and biological relevance. J Clin Invest 1990, 85:1709-1715.
3. Scanu AM: Proteolytic modifications of lipoprotein(a): potential relevance to its postulated athero-thrombogenic role. J Invest Med 1998, 46:359-363.
4. Marcovina SM, Albers JJ, Scanu AM, et al.: Use of a reference material proposed by the international federation of clinical chemistry and laboratory medicine to evaluate analytical methods for the determination of plasma lipoprotein(a). Clin Chem 2000, 46:1956-1967.
5. Scanu AM: Lipoprotein(a) - A genetically determined cardiovascular pathogen insearch of a function. J Lab Clin Med 1990, 116:142-146.
6. Utermann G: Lipoprotein(a). In The Metabolic and Molecular Basis of Inherited Disease. Edited by Scriver, CR, Beaudet AL, Sly WS, Valle D. New York: McGraw Hill; 1995:1887-1912.
7. Scanu AM, Edelstein C: Kringle-dependent structural and functional polymorphism of apolipoprotein. Biochim Biophys Acta 1995, 1256:1-12.
8. Scanu AM, Edelstein C: Learning about the structure and biology of human lipoprotein(a) through dissection by enzymes of the elastase family: facts and speculations. J Lipid Res 1997, 38:2193-2206.
9. Scanu AM, Pfaffinger D, Lee JC, Hinman J: A single point mutation (Trp72-Arg) in human apo(a) kringle 4-37 associated with a lysine binding defect in Lp(a). Biochim Biophys Acta 1994, 1227:41-45.
10. McLean JW, Tomlinson JE, Kuang W, et al.: cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 1987, 330:132-137.
11. Hobbs HH, White AL: Lipoprotein(a): intrigues and insights. Curr Opin Lipidol 1999, 10:225-236.
12. Krauss RM: Heterogeneity of plasma low density lipoproteins and atherosclerosis risk. Curr Opin Lipidol 1994, 5:339-349.
13. Berg K: Lp(a) lipoprotein - an overview. Chemistry and Physics of Lipids 1994, 67-68:9-16.
14. Nakajima K, Hinman J, Pfaffinger D, et al.: Changes in plasma triglyceride levels shift lipoprotein(a) density in parallel with that of low-density lipoprotein independently of apolipoprotein(a) size. Ather Thromb Vasc Biol 2001, in press.
15. Fong LG, Parthasarathy S, Witzum JL, Steinberg D: Nonenzymatic oxidative cleavage of peptide bonds in apoprotein B100. J Lipid Res 1987, 28:1466-1476.
16. Edelstein C, Nakajima K, Pfaffinger D, Scanu AM: Oxidative events cause degradation of apolipoprotein B100 but not apolipoprotein(a) and facilitate enzymatic cleavage of both proteins [Abstract]. Arterior Thromb Vasc Biol 2001, 21:635.
17. Aggerbeck LP, Kezdy FJ, Scanu AM: Enzymatic probes of lipoprotein structure: hydrolysis of human serum llowdensity lipoprotein-2 by phospholipase A2. J Biol Chem 1976, 251:3823-3830.
18. Tabas I: Nonoxidative modifications of lipoproteins in atherogenesis. Annu Rev Nutr 1999, 19:123-139.
19. Fless GM, Kirk EW, Klezovitch O, et al.: Effect of phospholipase A2 digestion on the conformation and lysine/fibrinogen binding properties of human lipoprotein(a). J Lipid Res 1999, 40:583-592.
20. Cushing GL, Gaubatz JW, Nava ML, et al.: Quantification and localization of apoproteins(a) and B in coronary artery bypass vein grafts resected at re-operation. Arteriosclerosis 1989, 9:593-603.
21. Rath M, Niendorf A, Reblin T, et al.: Detection and quantification of lipoprotrein(a) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis 1989, 9:579-592.
22. Pepin JM, Oneil JA, Hoff HF: Quantification of apo(a) and apoB in human atherosclerotic lesions. J Lipid Res 1991, 32:317-327.
23. Scanu AM: Lipoprotein(a): a potential bridge between the fields of atherosclerosis and thrombosis. Arch Pathol Lab Med 1988, 112:1045-1047.
24. Miles LA, Plow EF: Lp(a): an interloper into the fibrinolytic system? Thromb Haemost 1990, 63:331-335.
25. Haque NS, Zhang X, French DL, et al.: CC chemokine I-309 is the principal monocyte chemoattractant induced by apolipoprotein(a) in human vascular endothelial cells. Circulation 2000, 102:786-792.
26. Lawn MR, Scanu AM: Lipoprotein(a). In Atherosclerosis And Coronary Artery Disease. Edited by Fuster V, Ross R, Topol EJ. Philadelphia: Lippincott-Raven; 1996:151-161.
27. Scanu AM, Edelstein C, Klezovitch O: Dominant role of the C-terminal domain in the binding of apolipoprotein(a) to the protein core of proteoglycans and other members of the extracellular matrix. Trends Cardiovasc Med 2000, 9:196-200.
28. Buechler C, Ullrih H, Ritter M, et al.: Lipoprotein(a) upregulates the expression of the plasminogen activator inhibitor 2 in human blood monocytes. Blood 2001, 97:981-986.
29. Kurschinski DT, Dennen DA, Garcia M, Scanu AM: Plasma lipoprotein(a) and the Friedewald formula. Clin Chem 1989, 35:2157.
30. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the distribution of low density lipoprotein cholesterol in plasma without the use of the preparative centrifuge. Clin Chem 1972, 18:499-502.
31. Scanu AM: Lp(a), Friedewald formula and NCEP guidelines. Am J Cardiol 2001, 87:608-609.
32. Seman LJ, Jenner JL, McNamara JR, Schaefer EJ: Quantification of lipoprotein(a) in plasma by assaying cholesterol in Lectin-Bound plasma fraction. Clin Chem 1994, 40:400-403.
33. Fless GM, Snyder ML, Scanu AM: Enzyme-linked immunoassay for Lp(a). J Lipid Res 1989, 30:651-662.